cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cymabay Therapeutics Inc
20 own
34 watching
Current Price
$0
$0.1
(1.13%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
788.38M
52-Week High
52-Week High
11.22
52-Week Low
52-Week Low
1.81
Average Volume
Average Volume
0.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization788.38M
icon52-Week High11.22
icon52-Week Low1.81
iconAverage Volume0.03M
iconDividend Yield--
iconP/E Ratio--
What does the Cymabay Therapeutics Inc do?
Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. Its key clinical development candidates comprise MBX-8025, a selective agonist that is in a third Phase II clinical trial in patients with primary biliary cholangitis; and Arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The company's product candidate also includes MBX-2982, an oral, G-protein coupled receptor agonist to treat type II diabetes. Cymabay Therapeutics, Inc. has a development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products. The company was formerly known as Metabolex, Inc. Cymabay Therapeutics, Inc. was incorporated in 1988 and is based in Newark, California.
Read More
How much money does Cymabay Therapeutics Inc make?
News & Events about Cymabay Therapeutics Inc.
Globe Newswire
1month ago
NEWARK, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results from the ENHANCE phase 3 ...
Ticker Report
2 months ago
CymaBay Therapeutics (NASDAQ:CBAY Get Rating) had its price target lifted by HC Wainwright from $10.00 to $12.00 in a research note published on Friday, The Fly reports. Other equities research analysts also recently issued research reports about the company. Raymond James increased their ...
Ticker Report
3 months ago
CymaBay Therapeutics, Inc. (NASDAQ:CBAY Get Rating) Equities research analysts at Oppenheimer boosted their FY2024 earnings per share estimates for CymaBay Therapeutics in a research report issued to clients and investors on Monday, March 6th. Oppenheimer analyst J. Olson now expects...
Globe Newswire
3 months ago
NEWARK, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the Oppenheimer 33rd...
Globe Newswire
4 months ago
NEWARK, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Securities ...
Frequently Asked Questions
Frequently Asked Questions
What is Cymabay Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Cymabay Therapeutics Inc shares?
plus_minus_icon
How can I buy Cymabay Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Cymabay Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cymabay Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Cymabay Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Cymabay Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cymabay Therapeutics Inc?
plus_minus_icon
What percentage is Cymabay Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cymabay Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.1
(1.13%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Viking Therapeutics, Inc.
Viking Therapeutics, Inc.
$24.94
$0.15 (0.61 %)
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$1.02
$0.01 (1.49 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.56
$0.02 (0.59 %)
MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC
$9.30
$0.17 (1.86 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Viking Therapeutics, Inc.
Viking Therapeutics, Inc.
$24.94
$0.15 (0.61 %)
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$1.02
$0.01 (1.49 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.56
$0.02 (0.59 %)
MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC
$9.30
$0.17 (1.86 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00